Top

Cancer Chemotherapy and Pharmacology

Published in:

01-08-2021 | Original Article

Downregulation of SELENBP1 enhances oral squamous cell carcinoma chemoresistance through KEAP1–NRF2 signaling

Authors: Hui Zeng, Xubing Zhao, Chengfang Tang

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2021

Abstract

Purpose

Limited value is achieved in systemic chemotherapy for oral squamous cell carcinoma (OSCC), due to cancer cell resistance against cytotoxic agents. Tumor suppressor activities of selenium-binding protein 1 (SELENBP1) have been shown in multiple human cancers except for OSCC. The aim of this study is to clarify the biological functions and potential mechanism of SELENBP1 in OSCC.

Methods

SELENBP1 expression and its clinical significance in OSCC were analyzed from The Cancer Genome Atlas (TCGA) database. Quantitative polymerase chain reaction (qPCR) or western blot was applied to determine SELENBP1, NRF2 and KEAP1 mRNA or protein levels. Sulforhodamine B assay (SRB) was performed to examine the cytotoxic effects of 5-fluorouracil (5-FU) and cisplatin on OSCC cells. Luciferase reporter assay and chromatin immunoprecipitation (ChIP) assay were conducted to investigate the role of SELENBP1 in KEAP1 transcription.

Results

SELENBP1 downregulation is positively correlated with a poor prognosis for OSCC patients. SELENBP1 knockdown enhances resistance of OSCC cells to 5-FU and cisplatin, while SENENBP1 overexpression displays the opposite effects. Mechanistically, SELENBP1 reduces NRF2 protein levels by promoting its polyubiquitination and degradation. SELENBP1 induces KEAP1 transcription by binding to KEAP1 promoter. Downregulation of SELENBP1 is induced by miR-4786-3p binding to the 3′ untranslated region (UTR) of SELENBP1.

Conclusion

SENENBP1 is identified as a novel protective biomarker for OSCC patients. Targeting at the miR-4786-3p–SELENBP1–KEAP1–NRF2 signaling axis may enhance the efficacy of chemotherapy for OSCC.

Available only for authorised users

Siegel RL, Miller KD (2020) Jemal A (2020) Cancer statistics. CA Cancer J Clin 70(1):7–30. https://doi.org/10.3322/caac.21590CrossRefPubMed

Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR, Group TAXS (2011) Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: Long-term results of the tax 324 randomised phase 3 trial. Lancet Oncol 12(2):153–159. https://doi.org/10.1016/S1470-2045(10)70279-5CrossRef

Huang SH, O’Sullivan B (2013) Oral cancer: current role of radiotherapy and chemotherapy. Med Oral Patol Oral Cir Bucal 18(2):e233-240. https://doi.org/10.4317/medoral.18772CrossRefPubMedPubMedCentral

Wang C, Liu XQ, Hou JS, Wang JN, Huang HZ (2016) Molecular mechanisms of chemoresistance in oral cancer. Chin J Dent Res 19(1):25–33. https://doi.org/10.3290/j.cjdr.a35694CrossRefPubMed

Chang PW, Tsui SK, Liew C, Lee CC, Waye MM, Fung KP (1997) Isolation, characterization, and chromosomal mapping of a novel cdna clone encoding human selenium binding protein. J Cell Biochem 64(2):217–224. https://doi.org/10.1002/(sici)1097-4644(199702)64:2CrossRefPubMed

Zhang S, Li F, Younes M, Liu H, Chen C, Yao Q (2013) Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium. PLoS ONE 8(5):e63702-63713. https://doi.org/10.1371/journal.pone.0063702CrossRefPubMedPubMedCentral

Zhang J, Dong WG, Lin J (2011) Reduced selenium-binding protein 1 is associated with poor survival rate in gastric carcinoma. Med Oncol 28(2):481–487. https://doi.org/10.1007/s12032-010-9482-7CrossRefPubMed

Xia YJ, Ma YY, He XJ, Wang HJ, Ye ZY, Tao HQ (2011) Suppression of selenium-binding protein 1 in gastric cancer is associated with poor survival. Hum Pathol 42(11):1620–1628. https://doi.org/10.1016/j.humpath.2011.01.008CrossRefPubMed

Huang C, Ding G, Gu C, Zhou J, Kuang M, Ji Y, He Y, Kondo T, Fan J (2012) Decreased selenium-binding protein 1 enhances glutathione peroxidase 1 activity and downregulates hif-1alpha to promote hepatocellular carcinoma invasiveness. Clin Cancer Res 18(11):3042–3053. https://doi.org/10.1158/1078-0432.CCR-12-0183CrossRefPubMed

10.

Li T, Yang W, Li M, Byun DS, Tong C, Nasser S, Zhuang M, Arango D, Mariadason JM, Augenlicht LH (2008) Expression of selenium-binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer. Mol Nutr Food Res 52(11):1289–1299. https://doi.org/10.1002/mnfr.200700331CrossRefPubMed

11.

Chen G, Wang H, Miller CT, Thomas DG, Gharib TG, Misek DE, Giordano TJ, Orringer MB, Hanash SM, Beer DG (2004) Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. J Pathol 202(3):321–329. https://doi.org/10.1002/path.1524CrossRefPubMed

12.

Feng S, Wang S, Wang Y, Yang Q, Wang D, Li H (2018) Identification and expression of carbonic anhydrase 2, myosin regulatory light chain 2 and selenium-binding protein 1 in zebrafish danio rerio: Implication for age-related biomarkers. Gene Expr Patterns 29(1):47–58. https://doi.org/10.1016/j.gep.2018.04.007CrossRefPubMed

13.

Schott M, de Jel MM, Engelmann JC, Renner P, Geissler EK, Bosserhoff AK, Kuphal S (2018) Selenium-binding protein 1 is down-regulated in malignant melanoma. Oncotarget 9(12):10445–10456. https://doi.org/10.18632/oncotarget.23853CrossRefPubMedPubMedCentral

14.

Elhodaky M, Diamond AM (2018) Selenium-binding protein 1 in human health and disease. Int J Mol Sci 19(11):34–37. https://doi.org/10.3390/ijms19113437CrossRef

15.

Vichai V, Kirtikara K (2006) Sulforhodamine b colorimetric assay for cytotoxicity screening. Nat Protoc 1(3):1112–1116. https://doi.org/10.1038/nprot.2006.179CrossRefPubMed

16.

Chen WY, Lu R, Jiang X, Chen X, Meng N, Chen M, Xie S, Yan GR (2020) E3 ligase zfp91 inhibits hepatocellular carcinoma metabolism reprogramming by regulating pkm splicing. Theranostics 10(19):8558–8572. https://doi.org/10.7150/thno.44873CrossRefPubMedPubMedCentral

17.

Carlisi D, De Blasio A, Drago-Ferrante R, Di Fiore R, Buttitta G, Morreale M, Scerri C, Vento R, Tesoriere G (2017) Parthenolide prevents resistance of mda-mb231 cells to doxorubicin and mitoxantrone: the role of nrf2. Cell Death Discov 3(1):70–78. https://doi.org/10.1038/cddiscovery.2017.78CrossRef

18.

Jiang T, Chen N, Zhao F, Wang XJ, Kong B, Zheng W, Zhang DD (2010) High levels of nrf2 determine chemoresistance in type ii endometrial cancer. Cancer Res 70(13):5486–5496. https://doi.org/10.1158/0008-5472.CAN-10-0713CrossRefPubMedPubMedCentral

19.

Lian W, Liu X, Chen W (2019) Tnfalpha induces multidrug resistance-associated protein 4 expression through p38–e2f1-nrf2 signaling in obstructive cholestasis. Yonsei Med J 60(11):1045–1053. https://doi.org/10.3349/ymj.2019.60.11.1045CrossRefPubMedPubMedCentral

20.

Scott DC, Rhee DY, Duda DM, Kelsall IR, Olszewski JL, Paulo JA, de Jong A, Ovaa H, Alpi AF, Harper JW, Schulman BA (2016) Two distinct types of e3 ligases work in unison to regulate substrate ubiquitylation. Cell 166(5):1198–1214. https://doi.org/10.1016/j.cell.2016.07.027CrossRefPubMedPubMedCentral

21.

Zhi X, Zhao D, Wang Z, Zhou Z, Wang C, Chen W, Liu R, Chen C (2013) E3 ubiquitin ligase rnf126 promotes cancer cell proliferation by targeting the tumor suppressor p21 for ubiquitin-mediated degradation. Cancer Res 73(1):385–394. https://doi.org/10.1158/0008-5472.CAN-12-0562CrossRefPubMed

22.

Adam J, Hatipoglu E, O’Flaherty L, Ternette N, Sahgal N, Lockstone H, Baban D, Nye E, Stamp GW, Wolhuter K, Stevens M, Fischer R, Carmeliet P, Maxwell PH, Pugh CW, Frizzell N, Soga T, Kessler BM, El-Bahrawy M, Ratcliffe PJ, Pollard PJ (2011) Renal cyst formation in fh1-deficient mice is independent of the hif/phd pathway: Roles for fumarate in keap1 succination and nrf2 signaling. Cancer Cell 20(4):524–537. https://doi.org/10.1016/j.ccr.2011.09.006CrossRefPubMedPubMedCentral

23.

Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, Yamamoto M (1999) Keap1 represses nuclear activation of antioxidant responsive elements by nrf2 through binding to the amino-terminal neh2 domain. Genes Dev 13(1):76–86. https://doi.org/10.1101/gad.13.1.76CrossRefPubMedPubMedCentral

24.

Wang Y, Zhu W, Chen X, Wei G, Jiang G, Zhang G (2020) Selenium-binding protein 1 transcriptionally activates p21 expression via p53-independent mechanism and its frequent reduction associates with poor prognosis in bladder cancer. J Transl Med 18(1):17–30. https://doi.org/10.1186/s12967-020-02211-4CrossRefPubMedPubMedCentral

25.

Chen H, Lorton B, Gupta V, Shechter D (2017) A tgfbeta-prmt5-mep50 axis regulates cancer cell invasion through histone h3 and h4 arginine methylation coupled transcriptional activation and repression. Oncogene 36(3):373–386. https://doi.org/10.1038/onc.2016.205CrossRefPubMed

26.

Chaudhary K, Deb S, Moniaux N, Ponnusamy MP, Batra SK (2007) Human RNA polymerase II-associated factor complex: dysregulation in cancer. Oncogene 26(54):7499–7507. https://doi.org/10.1038/sj.onc.1210582CrossRefPubMed

27.

Ambros V (2004) The functions of animal micrornas. Nature 431(7006):350–355. https://doi.org/10.1038/nature02871CrossRefPubMed

28.

Zhu R, Zhao W, Fan F, Tang L, Liu J, Luo T, Deng J, Hu Y (2017) A 3-mirna signature predicts prognosis of pediatric and adolescent cytogenetically normal acute myeloid leukemia. Oncotarget 8(24):38902–38913. https://doi.org/10.18632/oncotarget.17151CrossRefPubMedPubMedCentral

29.

Silvers AL, Lin L, Bass AJ, Chen G, Wang Z, Thomas DG, Lin J, Giordano TJ, Orringer MB, Beer DG, Chang AC (2010) Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivity. Clin Cancer Res 16(7):2009–2021. https://doi.org/10.1158/1078-0432.CCR-09-2801CrossRefPubMedPubMedCentral

30.

Amar S, Ovadia O, Maier W, Ebstein R, Belmaker RH, Mishmar D, Agam G (2010) Copy number variation of the selenbp1 gene in schizophrenia. Behav Brain Funct 6(1):40–50. https://doi.org/10.1186/1744-9081-6-40CrossRefPubMedPubMedCentral

31.

Noman ASM, Parag RR, Rashid MI, Islam S, Rahman MZ, Chowdhury AA, Sultana A, Jerin C, Siddiqua A, Rahman L, Nayeem J, Akther S, Baidya S, Shil RK, Rahman M, Shirin A, Mahmud R, Hossain SMI, Sumi SA, Chowdhury A, Basher SB, Hasan A, Bithy S, Aklima J, Chowdhury N, Hasan MN, Banu T, Chowdhury S, Hossain MM, Yeger H, Farhat WA, Islam SS (2020) Chemotherapeutic resistance of head and neck squamous cell carcinoma is mediated by epcam induction driven by il-6/p62 associated nrf2-antioxidant pathway activation. Cell Death Dis 11(8):663–678. https://doi.org/10.1038/s41419-020-02907-xCrossRefPubMedPubMedCentral

32.

Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J, Blackford A, Goodman SN, Bunz F, Watson WH, Gabrielson E, Feinstein E, Biswal S (2008) Rnai-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 68(19):7975–7984. https://doi.org/10.1158/0008-5472.CAN-08-1401CrossRefPubMedPubMedCentral

33.

Ryoo IG, Lee SH (2016) Kwak MK (2016) Redox modulating nrf2: a potential mediator of cancer stem cell resistance. Oxid Med Cell Longev 1:153–167. https://doi.org/10.1155/2016/2428153CrossRef

34.

Roh JL, Kim EH, Jang H, Shin D (2017) Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol 11(1):254–262. https://doi.org/10.1016/j.redox.2016.12.010CrossRefPubMed

35.

Zhang DD, Lo SC, Cross JV, Templeton DJ, Hannink M (2004) Keap1 is a redox-regulated substrate adaptor protein for a cul3-dependent ubiquitin ligase complex. Mol Cell Biol 24(24):10941–10953. https://doi.org/10.1128/MCB.24.24.10941-10953.2004CrossRefPubMedPubMedCentral

36.

Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, Igarashi K, Yamamoto M (2004) Oxidative stress sensor keap1 functions as an adaptor for cul3-based e3 ligase to regulate proteasomal degradation of nrf2. Mol Cell Biol 24(16):7130–7139. https://doi.org/10.1128/MCB.24.16.7130-7139.2004CrossRefPubMedPubMedCentral

37.

Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA (2004) The keap1-btb protein is an adaptor that bridges nrf2 to a cul3-based e3 ligase: Oxidative stress sensing by a cul3-keap1 ligase. Mol Cell Biol 24(19):8477–8486. https://doi.org/10.1128/MCB.24.19.8477-8486.2004CrossRefPubMedPubMedCentral

Title: Downregulation of SELENBP1 enhances oral squamous cell carcinoma chemoresistance through KEAP1–NRF2 signaling
Authors: Hui Zeng
Xubing Zhao
Chengfang Tang
Publication date: 01-08-2021
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2021
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-021-04284-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2021

Exploratory analysis of target concentration of lenvatinib in the treatment of hepatocellular carcinoma

Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway

Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children’s Oncology Group Study ADVL06B1

Translational model of melphalan-induced gut toxicity reveals drug-host-microbe interactions that drive tissue injury and fever

MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism

Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas

Keynote webinar | Spotlight on antibody–drug conjugates in cancer